๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—† The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery โ—† GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons โ—† Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing โ—† Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines โ—† Trumpโ€™s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—† The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery โ—† GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons โ—† Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing โ—† Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines โ—† Trumpโ€™s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications โ—†
Updated 04 Jul 2026 ยท HPRA open data

Ustekinumab - Medicines in Ireland

49 authorised products containing Ustekinumab, from the HPRA register.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0โ€“9
Showing 49 authorised medicines
MedicineActive substanceLicence holderStatus
Fymskina 130 mg Concentrate for solution for infusion
EU/1/24/1862/003
Ustekinumab Formycon AG โ€”
Fymskina 45 mg Solution for injection
EU/1/24/1862/001
Ustekinumab Formycon AG โ€”
Fymskina 90 mg Solution for injection
EU/1/24/1862/002
Ustekinumab Formycon AG โ€”
Imuldosa 130 mg Concentrate for solution for infusion
EU/1/24/1872/003
Ustekinumab Accord Healthcare S.L.U. โ€”
Imuldosa 45 mg Solution for injection
EU/1/24/1872/001
Ustekinumab Accord Healthcare S.L.U. โ€”
Imuldosa 90 mg Solution for injection
EU/1/24/1872/002
Ustekinumab Accord Healthcare S.L.U. โ€”
Otulfi 130 mg Concentrate for solution for infusion
EU/1/24/1863/003
Ustekinumab Fresenius Kabi Deutschland GmbH โ€”
Otulfi 45 mg Solution for injection
EU/1/24/1863/001
Ustekinumab Fresenius Kabi Deutschland GmbH โ€”
Otulfi 45 mg Solution for injection pre-filled pen
EU/1/24/1863/005
Ustekinumab Fresenius Kabi Deutschland GmbH โ€”
Otulfi 90 mg Solution for injection
EU/1/24/1863/002
Ustekinumab Fresenius Kabi Deutschland GmbH โ€”
Otulfi 90 mg Solution for injection in Pre-filled pen
EU/1/24/1863/006
Ustekinumab Fresenius Kabi Deutschland GmbH โ€”
Pyzchiva 130 mg concentrate for solution for infusion
EU/1/24/1801/003
Ustekinumab Samsung Bioepis NL B.V. โ€”
Pyzchiva 45 mg solution for injection in pre-filled pen
EU/1/24/1801/004
Ustekinumab Samsung Bioepis NL B.V. โ€”
Pyzchiva 45 mg solution for injection in pre-filled syringe
EU/1/24/1801/001
Ustekinumab Samsung Bioepis NL B.V. โ€”
Pyzchiva 90 mg solution for injection in pre-filled pen
EU/1/24/1801/005
Ustekinumab Samsung Bioepis NL B.V. โ€”
Pyzchiva 90 mg solution for injection in pre-filled syringe
EU/1/24/1801/002
Ustekinumab Samsung Bioepis NL B.V. โ€”
Qoyvolma 130 mg concentrate for solution for infusion
EU/1/25/1925/003
Ustekinumab Celltrion Healthcare Hungary Kft. โ€”
Qoyvolma 45 mg solution for injection in pre-filled syringe
EU/1/25/1925/001
Ustekinumab Celltrion Healthcare Hungary Kft. โ€”
Qoyvolma 90 mg solution for injection in pre-filled syringe
EU/1/25/1925/002
Ustekinumab Celltrion Healthcare Hungary Kft. โ€”
STELARA 130 mg Concentrate for solution for infusion
EU/1/08/494/005
Ustekinumab Janssen-Cilag International NV โ€”
STELARA 45 mg Solution for injection
EU/1/08/494/003
Ustekinumab Janssen-Cilag International NV โ€”
STELARA 45 mg Solution for injection
EU/1/08/494/001
Ustekinumab Janssen-Cilag International NV โ€”
STELARA 90 mg Solution for injection
EU/1/08/494/004
Ustekinumab Janssen-Cilag International NV โ€”
STEQEYMA 130 mg Concentrate for solution for infusion
EU/1/24/1844/003
Ustekinumab Celltrion Healthcare Hungary Kft. โ€”
STEQEYMA 45 mg Solution for injection
EU/1/24/1844/001
Ustekinumab Celltrion Healthcare Hungary Kft. โ€”
STEQEYMA 90 mg Solution for injection
EU/1/24/1844/002
Ustekinumab Celltrion Healthcare Hungary Kft. โ€”
Usgena 130 mg concentrate for solution for infusion
EU/1/25/1987/005
Ustekinumab Stada Arzneimittel AG โ€”
Usgena 45 mg solution for injection
EU/1/25/1987/001
Ustekinumab Stada Arzneimittel AG โ€”
Usgena 45 mg solution for injection in pre-filled syringe
EU/1/25/1987/002
Ustekinumab Stada Arzneimittel AG โ€”
Usgena 90 mg solution for injection in pre-filled syringe
EU/1/25/1987/003-004
Ustekinumab Stada Arzneimittel AG โ€”
Usrenty 130 mg concentrate for solution for infusion
EU/1/25/1973/004
Ustekinumab Biocon Biologics Ireland Limited โ€”
Usrenty 45 mg solution for injection
EU/1/25/1973/001
Ustekinumab Biocon Biologics Ireland Limited โ€”
Usrenty 45 mg solution for injection in pre-filled syringe
EU/1/25/1973/002
Ustekinumab Biocon Biologics Ireland Limited โ€”
Usrenty 90 mg solution for injection in pre-filled syringe
EU/1/25/1973/003
Ustekinumab Biocon Biologics Ireland Limited โ€”
Usymro 130 mg concentrate for solution for infusion
EU/1/25/1957/004
Ustekinumab Gedeon Richter Plc โ€”
Usymro 45 mg solution for injection
EU/1/25/1957/001
Ustekinumab Gedeon Richter Plc โ€”
Usymro 45 mg solution for injection in pre-filled syringe
EU/1/25/1957/002
Ustekinumab Gedeon Richter Plc โ€”
Usymro 90 mg solution for injection in pre-filled syringe
EU/1/25/1957/003
Ustekinumab Gedeon Richter Plc โ€”
Uzpruvo 130 mg concentrate for solution for infusion
EU/1/23/1784/005
Ustekinumab Stada Arzneimittel AG โ€”
Uzpruvo 45 mg solution for injection in pre-filled syringe
EU/1/23/1784/001
Ustekinumab Stada Arzneimittel AG โ€”
Uzpruvo 90 mg solution for injection in pre-filled syringe
EU/1/23/1784/004
Ustekinumab Stada Arzneimittel AG โ€”
WEZENLA 130 mg Concentrate for solution for infusion
EU/1/24/1823/004
Ustekinumab Amgen Technology (Ireland) UC โ€”
WEZENLA 45 mg Solution for injection
EU/1/24/1823/001
Ustekinumab Amgen Technology (Ireland) UC โ€”
WEZENLA 45 mg Solution for injection pre-filled syringe
EU/1/24/1823/002
Ustekinumab Amgen Technology (Ireland) UC โ€”
WEZENLA 90 mg Solution for injection pre-filled syringe
EU/1/24/1823/003
Ustekinumab Amgen Technology (Ireland) UC โ€”
Yesintek 130 mg Concentrate for solution for infusion
EU/1/24/1892/004
Ustekinumab Biosimilar Collaborations Ireland Limited โ€”
Yesintek 45 mg Solution for injection
EU/1/24/1892/002
Ustekinumab Biosimilar Collaborations Ireland Limited โ€”
Yesintek 45 mg Solution for injection Subcutaneous use
EU/1/24/1892/001
Ustekinumab Biosimilar Collaborations Ireland Limited โ€”
Yesintek 90 mg Solution for injection
EU/1/24/1892/003
Ustekinumab Biosimilar Collaborations Ireland Limited โ€”
Cite this database

Priya Life Science (2026). Irish Medicines Database. Available at: https://priyalifescience.com/medicines (Accessed: 13 August 2026).

Data: Health Products Regulatory Authority (HPRA) open dataset (โ€œAuthorised or Transfer Pending Productsโ€), licensed CC BY 4.0, refreshed daily. Regulatory information only โ€” not medical advice.